OLIVAREZ COLLEGE TAGAYTAY
E-Library
ONLINE PUBLIC ACCESS CATALOG

Checkpoint inhibitor therapy: (Record no. 10280)

MARC details
000 -LEADER
fixed length control field 01122nam a22001817a 4500
005 - DATE AND TIME OF LATEST TRANSACTION
control field 20250226152756.0
008 - FIXED-LENGTH DATA ELEMENTS--GENERAL INFORMATION
fixed length control field 250226b ph ||||| |||| 00| 0 eng d
022 ## - INTERNATIONAL STANDARD SERIAL NUMBER
International Standard Serial Number 0360-4039
040 ## - CATALOGING SOURCE
Transcribing agency OCT
100 ## - MAIN ENTRY--PERSONAL NAME
Personal name Davis Lori
240 ## - UNIFORM TITLE
Uniform title Nursing 2024
Medium November 2024
245 ## - TITLE STATEMENT
Title Checkpoint inhibitor therapy:
Remainder of title Immune-related adverse event management/
Statement of responsibility, etc. Lori Davis, Mary Beth Casselbury, Sharon Wilson
300 ## - PHYSICAL DESCRIPTION
Extent Vol. 54 (11) pages 26-34 :
Other physical details Illustrations:
Dimensions 27 cm
500 ## - GENERAL NOTE
General note Treatment with immune checkpoint inhibitors for cancer is associated with a high prevalence of multiple immune-related toxicities. Immune-related adverse events (irAEs) can occur anytime during treatment and up to 3 months after treatment. This article discusses checkpoint inhibitor therapy and describes the implementation of a patient education program focused on recognizing immunotherapy irAEs and their toxicities.
650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name entry element Checkpoint inhibitor therapy, immune-related adverse events (irAEs), immune checkpoint inhibitors (ICIs), immunotherapy, oncology
700 ## - ADDED ENTRY--PERSONAL NAME
Personal name Casselbury Mary Beth, Wilson Sharon
942 ## - ADDED ENTRY ELEMENTS (KOHA)
Source of classification or shelving scheme Dewey Decimal Classification
Koha item type Continuing Resources
Suppress in OPAC No

No items available.